MedPath

Prevalence of Major Depression Among Immigrants in Santiago, Chile

Completed
Conditions
Major Depressive Disorder
Registration Number
NCT04114565
Lead Sponsor
Pontificia Universidad Catolica de Chile
Brief Summary

The general aim of this study is to explore the prevalence of major depressive disorder and the use of mental health services in the immigrant populations in the Metropolitan Region of Santiago, Chile.

The hypotheses are:

1. A healthy immigrant effect will be observed in the studied population by which their prevalence of major depressive disorder will be lower than the prevalence in the general Chilean population.

2. A significant association will be observed between the loss of socio-economic position after migration and a greater probability of major depressive disorder.

3. A significant association will be observed between the report of victimization experience(s) in the previous year and a greater probability of major depressive disorder.

4. A significant association will be observed between financial difficulties and a greater probability of major depressive disorder.

The sampling framework of the Chilean National Institute of Statistics (INE) from the 2016 Census will be used for the purpose of this research. The sampling units are as follows:

1. Primary sampling units (PSUs): conglomerates or groups of adjoining houses, organized in spatial blocks (200 households on average)

2. Secondary sampling units (SSUs): individual households within each of the conglomerates selected in the first stage

3. Final sampling units: persons meeting the study's inclusion criteria Multi-stage random probability sampling involving a 3-stage sampling design will be used - first, the sampling of the primary sampling units (PSUs); second, the sampling of households within the selected PSUs and finally, the random sampling of a household member.

Participants (n=1,100) will then take part in a 45-minute interview. This interview will be a household survey using the modular version of the Composite International Diagnostic Interview (WHO-CIDI) looking at exploring a broad spectrum of factors traditionally associated with increased risk of affective disorders:

1. Sociodemographics

2. Finance

3. Variation in socioeconomic position

4. Experience of victimization

5. Discrimination

6. Experience of childhood adversity

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1092
Inclusion Criteria
  • Country of birth other than Chile
  • Time since arrival to Chile: 3 months
Exclusion Criteria
  • Unable to understand Spanish

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major Depressive Disorderbaseline

Assessed using the World Health Organisation Composite International Diagnostic Interview (WHO-CIDI)

Anxiety symptomsbaseline

Assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7).

The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.

Any affective/mood disorderbaseline

Assessed using the WHO-CIDI

Suicidal ideation, plans and attemptsbaseline

Assessed using the WHO-CIDI

Depressive symptomsbaseline

Assessed using the nine-item Patient Health Questionnaire (PHQ-9).

The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.

Secondary Outcome Measures
NameTimeMethod
Hazardous/harmful drinkingbaseline

Assessed using the Alcohol Use Disorders Identification Test (AUDIT)

Mental wellbeingbaseline

Assessed using the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS).

The 14 Items are scored on a range from 1 to 5, providing a total score between 14 and 70 with higher values indicating higher mental well-being.

Mental health service usebaseline

Assessed using items of the Services Module of the WHO-CIDI

Trial Locations

Locations (1)

Pontificia Universidad Catolica de Chile

🇨🇱

Santiago, RM, Chile

© Copyright 2025. All Rights Reserved by MedPath